EN DE
Watch Tatva Chintan Pharma Chem Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Tatva Chintan Pharma Chem Limited (TATVA) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Tatva Chintan Pharma Chem Limited stock ₹247, price ₹1,661, that is 85.1% below the price, quality 49 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials IN · ISIN INE0GK401011

TC Tatva Chintan Pharma Chem Limited logo Thin data Nov 14, 2026

Tatva Chintan Pharma Chem Limited

TATVA · NSE

Far too expensive (fair value 85% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Last quarter vs. a year ago: revenue +76%, profit +116%. 
Quality 49/100 
Expensive Growth (revenue 5y +11.0 %/yr in INR) 
Thin margins · 9.7% net margin (TTM) 
0.1% dividend yield · Token dividend
Mixed vs. peers (6/13) 
Moderate moat 45/100 · thin data
Fair value ₹247.36 · Strongly overvalued 
Negative free cash flow 
Thin data 
Extreme value⟳ Cyclical
Watch Tatva Chintan Pharma Chem Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹2,860 ₹635.60 Fair Value ₹247.36 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range ₹635.60 – ₹2,860 · fair‑value band ₹229.22 – ₹321.57 · the ₹1,661 price screens above the ₹247.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Tatva Chintan Pharma Chem in your weekly email

Every Wednesday you see whether Tatva Chintan Pharma Chem is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally.

Show moreShow less

It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants.

The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.

Stock analysis

Tatva Chintan Pharma Chem Limited (TATVA) currently trades at ₹1,661, while our model-based Fair Value estimate is ₹247.36, 85% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ₹305.62 per share, and 0 of the 16 models we run sit above the ₹1,661 price.

Bear case: the Asset-Based group reads lowest at ₹54.54, and 16 of the 16 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹229.22 (bear) to ₹321.57 (bull), the price of ₹1,661 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Basic Materials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Tatva Chintan Pharma Chem Limited reported revenue of ₹5.1B in FY2026 versus ₹4.3B in FY2022, a compound +3.9%/yr. Reported net income was ₹421M in FY2026, compounding −18.6%/yr from FY2022.

Key figures

Market cap ₹38.8B (≈ $414M) Small · P/E ratio 61.7 · P/S ratio 5.98 · EPS (TTM) ₹26.90 · Dividend yield 0.1% · Net margin 9.7% · Return on equity 8.0% · Return on assets (EBIT) 14.6% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 58% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at −85%, TATVA screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (₹11.22 to ₹993.84). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹229.22 Fair Value ₹247.36 Bull ₹321.57
Price ₹1,661 · Downside -85.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹15.76 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ₹230.67 ₹224.38 ₹233.33 76
EPV ₹129.27 ₹144.77 ₹157.38 74
ROIC Compounder ₹129.27 ₹144.77 ₹157.38 72
All 16 models by family
Earnings-Based
Graham-Dodd ₹122.25 ₹435.24 ₹586.11 64
Lynch FV ₹110.30 ₹157.57 ₹204.84 61
PEG = 1.0 ₹110.30 ₹157.57 ₹204.84 57
EPV ₹129.27 ₹144.77 ₹157.38 74
Dividend Discount
Gordon GGM ₹7.04 ₹11.86 ₹15.47 68
DDM Multi-Stage ₹7.04 ₹11.22 ₹12.76 67
Multiples
P/E Multiple ₹229.22 ₹305.62 ₹382.03 63
P/S Multiple ₹229.22 ₹305.62 ₹382.03 58
P/B Multiple ₹745.38 ₹993.84 ₹1,242 55
EV/EBIT ₹205.06 ₹289.32 ₹373.57 65
EV/EBITDA ₹250.98 ₹350.55 ₹450.11 67
EV/Revenue ₹171.36 ₹265.24 ₹359.13 53
Asset-Based
NCAV (Graham) ₹36.00 ₹54.54 ₹68.17 54
Economic Profit
Residual Income ₹230.67 ₹224.38 ₹233.33 76
ROIC Compounder ₹129.27 ₹144.77 ₹157.38 72
Growth Earnings
Growth-Adj P/E ₹173.15 ₹247.36 ₹321.57 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 35
How much profit the company makes from its sales and capital
Quality Growth 72
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 79
Debt, balance sheet and risk of trouble
Investment 25
Does it invest with discipline instead of growing at any price?
Low Volatility 60
How calm the share price moves, does not count
Price momentum 61
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 52
Distance to the 52-week high, does not count
New shares 73
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 45/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2021 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.9%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−7.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.1%
Dividend (yield on the price)0.1%

TATVA screens overvalued: fair value 85% below the price. Compare with Linde plc →

Compare Tatva Chintan Pharma Chem Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 756 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −85.1% · Bottom 25%
Profitability
Return on equity (12 months) 8.0% · Above median
Return on assets 4.2% · Above median
Net margin (12 months) 9.7% · Above median
Operating margin (12 months) 13.8% · Above median
Growth and dividend
Revenue growth (quarter YoY) 75.9% · Top 25%
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/E (12 months) 61.7× · Priciest 25%
P/B 4.97× · Priciest 25%
P/S (12 months) 5.98× · Priciest 25%
EV/EBITDA 30.4× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)100 · sector 69
PAST (return on equity)32 · sector 26
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)2 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wanhua Chemical Group 600309 ¥69.50 ¥68.03 −2% vs TATVA
Linde plc LIN $523.46 $446.62 −15% vs TATVA
PPG Industries, Inc PPG $121.97 $77.68 −36% vs TATVA
DSM-Firmenich AG DSFIR CHF 96.60 CHF 58.32 −40% vs TATVA
Asian Paints Limited ASIANPAINT ₹2,573 ₹1,479 −43% vs TATVA
The Sherwin-Williams Company SHW $350.54 $152.59 −56% vs TATVA
Givaudan SA GIVN CHF 4,091 CHF 1,618 −60% vs TATVA
EMS-CHEMIE HOLDING AG EMSN CHF 839.00 CHF 284.63 −66% vs TATVA
Ecolab Inc ECL $308.41 $97.18 −68% vs TATVA
Air Products and Chemicals, Inc APD $313.90 $75.33 −76% vs TATVA

Explore undervalued stocks

More undervalued Basic Materials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tatva Chintan Pharma Chem Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Tatva Chintan Pharma Chem Limited Fair Value". https://www.fairvalue-calculator.com/stock/TATVA

Frequently asked questions

Is Tatva Chintan Pharma Chem Limited (TATVA) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of ₹247.36 versus a price of ₹1,661, about 85% lower (overvalued).
What is the fair value of TATVA?
Our model-based fair value for Tatva Chintan Pharma Chem Limited is ₹247.36 (as of Nov 14, 2026), built from audited fundamentals. The current price: ₹1,661.
What is the quality score of TATVA?
Tatva Chintan Pharma Chem Limited has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tatva Chintan Pharma Chem Limited (TATVA)?
Our model-based price target is the fair value of ₹247.36 (as of Nov 14, 2026) from 16 valuation models. Cautious scenario ₹229.22, optimistic scenario ₹321.57. It is a calculation from audited fundamentals, not an analyst target.
What is the Tatva Chintan Pharma Chem Limited stock forecast for 2026?
Our models put fair value at ₹247.36, about 85% lower versus a price of ₹1,661 (overvalued). Cautious scenario ₹229.22, optimistic scenario ₹321.57. The calculation is refreshed regularly with new filings.
What is the revenue of Tatva Chintan Pharma Chem Limited (TATVA)?
Tatva Chintan Pharma Chem Limited reported trailing-twelve-month revenue of about ₹6.5B (latest available figure, as of Nov 14, 2026).
Does Tatva Chintan Pharma Chem Limited pay a dividend?
Tatva Chintan Pharma Chem Limited currently shows a dividend yield of 0.12% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of Tatva Chintan Pharma Chem Limited (TATVA) and when is the ex-dividend date?
Tatva Chintan Pharma Chem Limited pays a dividend of ₹2.00 per share a year, a dividend yield of 0.1%. The last ex-dividend date was Sep 11, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 7.4% of earnings. Our assessment: Token dividend. At a yield of 0.1% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.1% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Tatva Chintan Pharma Chem Limited (TATVA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tatva Chintan Pharma Chem Limited it is ₹247.36 per share (as of Nov 14, 2026), against a price of ₹1,661. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Tatva Chintan Pharma Chem Limited stock overvalued or undervalued in 2026?
As of Nov 14, 2026, TATVA trades above its calculated fair value: price ₹1,661, fair value ₹247.36, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TATVA?
No. The price is what the market pays today (₹1,661); the fair value is what the company's own numbers justify (₹247.36). For Tatva Chintan Pharma Chem Limited the two are ₹1,413 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tatva Chintan Pharma Chem Limited worth?
The market values Tatva Chintan Pharma Chem Limited at about ₹38.8B (market capitalisation, as of Nov 14, 2026). Per share that is ₹1,661; our models calculate a fair value of ₹247.36 per share.
What do the bullish and bearish scenarios say about TATVA?
Our models span a range for Tatva Chintan Pharma Chem Limited: cautious scenario ₹229.22, base ₹247.36, optimistic ₹321.57 per share (as of Nov 14, 2026, price ₹1,661). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TATVA?
Tatva Chintan Pharma Chem Limited trades at a price-to-earnings ratio of 61.7 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹247.36 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2022 to 2026), reported earnings, FY2026 ex one-offs: 81.3. Other multiples: P/B 5.0, P/S 6.0, EV/EBITDA 30.4.
How solid is the balance sheet of Tatva Chintan Pharma Chem Limited (TATVA)?
Balance-sheet figures for Tatva Chintan Pharma Chem Limited (as of Nov 14, 2026): return on equity 8.0%, debt of 0.01 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is TATVA from its 52-week high?
Tatva Chintan Pharma Chem Limited trades at ₹1,661, about 17% below its 52-week high of ₹1,991 and 58% above the low of ₹1,051 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹247.36 is for.
Which stocks are comparable to Tatva Chintan Pharma Chem Limited?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tatva Chintan Pharma Chem Limited stock attractive at the current price?
The data as of Nov 14, 2026: price ₹1,661, calculated fair value ₹247.36 (−85%), Quality Score 49/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TATVA calculated?
We run Tatva Chintan Pharma Chem Limited through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹247.36 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Tatva Chintan Pharma Chem Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tatva Chintan Pharma Chem Limited (TATVA)?
The closing price on Nov 16, 2026 was ₹1,661. Our model-based fair value is ₹247.36, about 85% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tatva Chintan Pharma Chem Limited right now?
The price sits above even our optimistic bull case (₹321.57). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Tatva Chintan Pharma Chem Limited

How large is the market capitalisation of Tatva Chintan Pharma Chem Limited (TATVA)?
The market capitalisation of Tatva Chintan Pharma Chem Limited is ₹38.8B (≈ $414M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tatva Chintan Pharma Chem Limited (TATVA)?
The price-to-sales ratio of Tatva Chintan Pharma Chem Limited is 5.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tatva Chintan Pharma Chem Limited (TATVA)?
Earnings per share at Tatva Chintan Pharma Chem Limited are ₹26.90 (price ÷ EPS = P/E 61.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tatva Chintan Pharma Chem Limited (TATVA)?
The dividend yield of Tatva Chintan Pharma Chem Limited is 0.1% (payout 7.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tatva Chintan Pharma Chem Limited (TATVA)?
The net margin of Tatva Chintan Pharma Chem Limited is 9.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tatva Chintan Pharma Chem Limited (TATVA)?
The return on equity (ROE) of Tatva Chintan Pharma Chem Limited is 8.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tatva Chintan Pharma Chem Limited (TATVA)?
On an EBIT basis the return on assets of Tatva Chintan Pharma Chem Limited is 14.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tatva Chintan Pharma Chem Limited (TATVA)?
The operating margin of Tatva Chintan Pharma Chem Limited is 13.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tatva Chintan Pharma Chem Limited (TATVA)?
Revenue at Tatva Chintan Pharma Chem Limited is growing 75.9% versus a year earlier (3y avg +6.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tatva Chintan Pharma Chem Limited (TATVA)?
Earnings per share at Tatva Chintan Pharma Chem Limited are growing 116% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Tatva Chintan Pharma Chem Limited (TATVA) generate?
The free cash flow of Tatva Chintan Pharma Chem Limited is −₹841M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tatva Chintan Pharma Chem Limited (TATVA) carry?
The net debt of Tatva Chintan Pharma Chem Limited is ₹1.1B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Tatva Chintan Pharma Chem Limited in the live analysis

One click puts Tatva Chintan Pharma Chem Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.